Multidrug resistance protein MdtM adds to the repertoire of antiporters involved in alkaline pH homeostasis in Escherichia coli

Megan Jordan

Institute of Pharmacology, Toxicology and Pharmacy,
Ludwig-Maximilians-University, Munich, Germany

01-01-2013

1 Abstract

SAN DIEGO - Decreasing inflammatory mediators are on the rise in the neuropathy that afflicts Type 2 diabetes, according to a new study from the Juvenile Diabetes Research Foundation.
While the study's findings are preliminary and have not been completely verified, preliminary work suggested an overall increase in inflammatory mediators - called cytokines - and their interactions with certain functions that affect the body's response to nerve dysfunction.
During a severe spike in inflammatory mediators in the blood, diabetic complications can mount - including a syndrome called chronic nerve disease (CHRD), which is tied to errors in nerve function in diabetes. CHRD symptoms can be deadly, leading to heart attacks and stroke.
As the team at the Diabetes Center at Scripps Research Institute examined tissue samples from healthy volunteers, they found that several inflammatory mediators (known as interleukin-6, interleukin-8, interleukin-15, interleukin-26 and interleukin-24) were produced in greater levels in areas where the body's responses to nerve injury was disrupted.
Among the inflammatory mediators produced in this "resource-dense" area are interleukin-9, interleukin-13, interleukin-24, interleukin-26, interleukin-27, interleukin-32, interleukin-35, interleukin-32, interleukin-37, interleukin-34, interleukin-34, interleukin-36, interleukin-33, interleukin-33, interleukin-34, interleukin-35, interleukin-34, interleukin-36, interleukin-35, interleukin-38, interleukin-39, interleukin-38, interleukin-39, interleukin-37, interleukin-36,

interleukin-36, interleukin

1.1 Image Analysis



Figure 1: A Man Is Holding A Cat In His Arms